FDA OK's Impavido in leishmaniasis; Knight wins priority voucher
This article was originally published in Scrip
The FDA late on 19 March granted approval to Knight Therapeutics to market Impavido (miltefosine) as a treatment for cutaneous, mucosal and visceral leishmaniasis, a parasitic disease transmitted by the phlebotomine sand flies and is found in parts of the tropics, subtropics and southern Europe.
You may also be interested in...
KaloBios Pharmaceuticals Inc.'s CEO Dr Cameron Durrant has ticked off two major tasks from his to-do list in his bid to turn the company around after it was caught in the firestorm of Martin Shkreli's fall from grace. He talks to Scrip about the company's strategy, his vision of a responsible pricing model, and the possibility that KaloBios' actions might help rehabilitate pharma's image.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.